Yu (Ray) Zuo (@RayZuoMD) header
Yu (Ray) Zuo (@RayZuoMD) profile picture

Rheumatologist, physician scientist @umichmedicine #antiphospholipid syndrome #COVID-19 #Neutrophils #NETs

Ann Arbor, MI
Joined July 2017
Photo by Yu (Ray) Zuo (@RayZuoMD)Photo by Yu (Ray) Zuo (@RayZuoMD)Photo by Yu (Ray) Zuo (@RayZuoMD)Photo by Yu (Ray) Zuo (@RayZuoMD)Photo by Yu (Ray) Zuo (@RayZuoMD)Photo by Yu (Ray) Zuo (@RayZuoMD)Photo by Yu (Ray) Zuo (@RayZuoMD)Photo by Yu (Ray) Zuo (@RayZuoMD)Photo by Yu (Ray) Zuo (@RayZuoMD)Photo by Yu (Ray) Zuo (@RayZuoMD)
ICYMI the NOURISH: Autoimmunity Digital Health Challenge is open to everyone including #engineeringstudents and #autoimmune patients
NIH invites innovators to join the NOURISH: Autoimmunity Digital Health Challenge! Develop digital health tools that help people living with or at risk for autoimmune diseases monitor diet, nutrition & symptoms. 💰 Up to $650K in total prizes 🏆 Up to 10 Phase 1 awards of $20K 🔗 nourishchallenge.org
1
6
910
#Medscape medical news reporting on our @TheLancetRheum manuscript for #cardiovascular risk control in #Antiphospholipid syndrome with a great discussion by @RayZuoMD medscape.com/viewarticle/too…
Excited to have led this initiative and grateful for all centres' contributions to a multiethnic study of 1001 patients with #APS, underlining the need for #cardiovascular risk management in primary APS and #SLE/APS. @TheLancetRheum thelancet.com/journals/lanrh…
5
14
1,054
RNA-seq study of aPL-positive patients identified 4 distinct clusters defined by gene expression modules & predicted immune cell compositions, offering potential to stratify APS & aPL-positive patients based on whole-blood transcriptomic profiles A&R doi.org/10.1002/art.70021
3
4
1
12
3,582
❤️👀 @CircAHA Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling ahajournals.org/doi/10.1161/…
1
10
1
19
1,439
#CatastrophicAPS affects <1% of #APS patients, causing rapid multi-organ #thrombosis. Mark’s story shows the value of coordinated care, incl. @RayZuoMD (@umichmedicine). We’ve previously shared his work; we thank him for his work helping the APS community. cutt.ly/8rG4mPQT
3
5
343
Calprotectin may serve as a mechanistically informed biomarker for atherosclerotic cardiovascular disease, independent of traditional and contemporary cardiovascular risk factors and biomarkers. ja.ma/4054WbW @dranandrohatgi
2
6
18
2,032
🩸👀 We wrote a paper for @BloodAdvances about antiphospholipid syndrome (APS), platelets, and purinergic signaling, with an eye toward potential therapeutic targets. See the Replies for a link to the article...
4
20
1
56
3,054
NEW EPISODE! @jasonsknight joins the podcast to break down the evolving science of antiphospholipid syndrome & its treatment. From antibodies to clinical trials—this is #APS like you’ve never heard it before. LISTEN NOW → acr.tw/3GxkWg8 @ACR_Journals
9
1
28
2,427
A great story showcasing the cutting-edge work coming out of the #APS Program and the APS Research Labs, led by Dr. @jasonsknight and Dr. @RayZuoMD.
Catastrophic antiphospholipid syndrome completely transformed Mark Hall’s daily life. But access to comprehensive care at U-M Health has been pivotal in treating his condition and redefining what it means to live with APS. Read Mark's story on our blog: michmed.org/JDkYV
2
1
3
730
Catastrophic antiphospholipid syndrome completely transformed Mark Hall’s daily life. But access to comprehensive care at U-M Health has been pivotal in treating his condition and redefining what it means to live with APS. Read Mark's story on our blog: michmed.org/JDkYV
1
5
1
12
1,818
June is #APSAwareness Month! Check out the latest APS Program Update, featuring our investigators in a special article with @APSFA, add'l news & achievements, a patient's story about living with APS & What I’m Reading in APS Research by Dr. Ajay Tambralli. conta.cc/4jUou9U
2
5
444
Research shows #calprotectin, a marker of #NeutrophilActivation, as a potential early indicator of #AtheroscleroticCardiovascularDisease. Elevated calprotectin levels were shown to predict future #HeartDisease risk, even in individuals without symptoms: cutt.ly/arx5jbId
5
8
624
Can GLP-1 agonists be considered for weight loss in patients with #APS? @RayZuoMD highlights that while data is limited, early evidence shows GLP-1 receptor agonists do not appear to increase thrombotic risk & may help reduce inflammation: cutt.ly/prpCC327 @umichmedicine
2
4
269
Read the latest #APS Program Update that features Dr. Jacqueline Madison's participation at the Pediatric APS Consensus Conference, APS Program Community Q&A Series on GLP-1 drugs by Dr. @RayZuoMD & Dr. Lauren Shevell & Q&A from Dr. @jasonsknight's inbox. conta.cc/4hKpI7f
5
5
749
On my way to the Deep South for an exciting day of rheumatology tomorrow 🧐
1
15
966
Read the new #APS Program Update that includes the lab's latest news & achievements, recordings of their recent lectures & talks, #ACR24 highlights, and What I’m Reading in APS Research written by Dr. Ajay Tambralli. conta.cc/4ird0vb
4
5
747
Yikes we have a lot of people presenting at #ACR24 this year. Way to go Michigan APS team 〽️🫡
4
42
2,750
Check out the latest #APS Program Update showcasing the lab's latest news & achievements, their upcoming presentations at #ACR24, and recent lectures, including the presentations given at the APS Research Conversation & Lab Tour they hosted in October. conta.cc/48sIWdI
3
2
11
1,091
My friends being recognized by Dr. Blackwell! ⁦〽️😤 ⁦@UMIntMed⁩ ⁦@RayZuoMD⁩ ⁦@elizatsou⁩
1
3
14
1,120
1
1
5
380